Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Cisplatin + Irinotecan + Krestin in ED-SCLC
NCT00546130Phase 2Unknown
- Sponsor
- University of Toyama
- Start
- Nov 2007
- Primary completion
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes, Microbiome-Derived Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polysaccharide k in small cell lung cancer (SCLC), sponsored by University of Toyama. Primary endpoint: Overall Survival Rate at 1 year. Status: unknown.
02
Drugs
polysaccharide k
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00546130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00546130.